<DOC>
	<DOCNO>NCT02029924</DOCNO>
	<brief_summary>The addition Biochaperone insulin lispro may accelerate onset shorten duration action insulin lispro due facilitation absorption insulin subcutaneous injection . The aim trial ass efficacy safety BioChaperone insulin lispro subject Type 1 diabetes dose 0.2 U/Kg . This trial single-center , randomise , double-blinded , two-treatment , two-period cross-over , 6-hour euglycaemic glucose clamp trial subject Type 1 diabetes mellitus . Each subject randomly allocate single dose BioChaperone insulin lispro 0.2 U/Kg single dose Humalog® 0.2 U/Kg 2 separate dose visit .</brief_summary>
	<brief_title>A Double-blinded , Randomised , Two -Period Crossover Euglycemic Clamp Trial Investigating Pharmacokinetics , Glucodynamics Safety BioChaperone Insulin Lispro Insulin Lispro ( Humalog® ) Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Type 1 diabetes mellitus least 12 month . Treated multiple daily insulin injection insulin pump least 12 month . Body Mass Index ( BMI ) : 18.028.0 Kg/m² . Type 2 diabetes mellitus . Receipt investigational product within 3 month prior first dose . Clinically significant abnormality judge investigator . Any systemic treatment drug know interfere glucose metabolism . History alcoholism , drug/chemical abuse per Investigator 's judgement . Use tobacco nicotinecontained product within 5 year prior screen . Blood plasma donation past month 500 mL within 3 month prior screen .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>